TAO Synergies Inc (TAOX)

NASD · Financial · Capital Markets · USA

TAO Synergies Inc is a micro cap company (market value under $300 million) in the Capital Markets industry.

TAO Synergies Inc. was historically a biopharmaceutical company developing Bryostatin-1 for Alzheimer's disease and related conditions. The company now accumulates and stakes TAO tokens through a decentralized blockchain network for machine learning and artificial intelligence.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the TAO Synergies Inc stock.

Our verdict on TAOX

Not valued: We cannot value this company yet.

We do not publish a value for this company: its filings cover one fiscal year and projecting growth needs four in a row.

ETFs with the most weight in TAOX

1 more funds hold it; the full list is part of the paid plan.

Browse

Peers in Capital Markets

All 96 Capital Markets stocks

Cheaper than TAOX in Capital Markets

30 more in this industry show a wider margin of safety.

Is TAOX undervalued or overvalued?

We do not publish a verdict on TAOX yet. A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive cover one fiscal year so far; the next annual report should close the gap. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.

What is the intrinsic value of TAOX?

We do not publish one (as of the 2026-11-17 close). A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive cover one fiscal year so far; the next annual report should close the gap. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.